Trubion Pharmaceuticals, Inc. ("Trubion" or the Company) is a biopharmaceutical company developing protein-based therapies to treat autoimmune and inflammatory diseases and cancer.

According to a press release dated October 05, 2010, the Complaint charges Trubion and Trubion’s board of directors with, among other things, violations of the Securities Exchange Act of 1934 and Rule 14a-9. In particular, the Complaint alleges that the Defendants have issued materially false and misleading statements regarding the proposed transaction wherein Trubion intends to merge with Emergent.

On December 01, 2010, the Court issued a Corrected Stipulation and Order Staying Case until after the State Court decides whether to finally approve a settlement.

On September 09, 2011, this case was dismissed pursuant to Federal Rule of Civil Procedure 41(a) and 41(b), after submission of a Motion to Dismiss by the Plaintiff.